TAT Technologies (TATT) announces 4.15 million share public offering

TAT Technologies Ltd. (Nasdaq: TATT) (TASE: TATT) ("TAT" or the "Company"), a leading provider of products and services to the commercial and military aerospace and ground defense industries, announced today that it has commenced an underwritten public offering of ordinary shares. 1,625,000 ordinary shares are being offered by TAT and 2,525,000 ordinary shares are being offered by FIMI Opportunity V, L.P. and FIMI Israel Opportunity Five, Limited Partnership (the "Selling Shareholders"). TAT and the Selling Shareholders intend to grant the underwriters an option to purchase up to an additional 242,298 and 380,202 ordinary shares, respectively, at the public offering price less the underwriting discount and commissions.

TAT intends to use the net proceeds that it will receive from the offering for general corporate purposes, including working capital and capital expenditures. TAT will not receive any proceeds from the sale of ordinary shares being offered by the Selling Shareholders.

The offering is subject to market and other conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering.

Stifel, Nicolaus & Company, Incorporated and Truist Securities, Inc. are acting joint book-running managers of this offering. The Benchmark Company, LLC and Lake Street Capital Markets, LLC are acting as passive book-running managers.

A registration statement on Form F-3 (File No. 333-286699) relating to the ordinary shares to be sold in the proposed offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on April 25, 2025. The offering will be made only by means of a prospectus. A copy of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, a copy of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at [email protected]; or Truist Securities, Inc., Attention: Equity Capital Markets, 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326 at (800) 685-4786 or by email to [email protected].

You May Also Be Interested In

• AiRWA receives Nasdaq deficiency notice over late 10-K filing
• Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
• Tenon Medical closes $3M private placement with institutional investor